Literature DB >> 12477714

The transcriptional co-activators CREB-binding protein (CBP) and p300 play a critical role in cardiac hypertrophy that is dependent on their histone acetyltransferase activity.

Rosalind J Gusterson1, Elen Jazrawi, Ian M Adcock, David S Latchman.   

Abstract

The CBP and p300 proteins are transcriptional co-activators that are involved in a variety of transcriptional pathways in development and in response to specific signaling pathways. We have previously demonstrated that the ability of both these factors to stimulate transcription is greatly enhanced by treatment of cardiac cells with the hypertrophic agent phenylephrine (PE). Here, we show that inhibition of either CBP or p300 with antisense or dominant negative mutant constructs inhibits PE-induced hypertrophy as assayed by atrial naturetic protein production, cardiac cell protein:DNA ratio and cell size. Furthermore, we show that overexpression of CBP or p300 can induce hypertrophy and that this effect requires their histone acetyltransferase (HAT) activity. Moreover, we show that PE can directly enhance CBP HAT activity and that artificial enhancement of HAT activity is sufficient to induce hypertrophy. Hence, CBP and p300 play an essential role in hypertrophy induced by PE, and this effect is mediated via PE-induced enhancement of their HAT activity. This is the first time a role for these factors, and their HAT activity, in hypertrophy has been directly demonstrated.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12477714     DOI: 10.1074/jbc.M211762200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  52 in total

1.  Calcium-mediated histone modifications regulate alternative splicing in cardiomyocytes.

Authors:  Alok Sharma; Hieu Nguyen; Cuiyu Geng; Melissa N Hinman; Guangbin Luo; Hua Lou
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-03       Impact factor: 11.205

Review 2.  Re-employment of developmental transcription factors in adult heart disease.

Authors:  Toru Oka; Jian Xu; Jeffery D Molkentin
Journal:  Semin Cell Dev Biol       Date:  2006-11-24       Impact factor: 7.727

3.  Epigenetic abnormalities in cardiac hypertrophy and heart failure.

Authors:  Hiroyuki Mano
Journal:  Environ Health Prev Med       Date:  2007-12-11       Impact factor: 3.674

Review 4.  The emerging role of epigenetics in cardiovascular disease.

Authors:  Charbel Abi Khalil
Journal:  Ther Adv Chronic Dis       Date:  2014-07       Impact factor: 5.091

Review 5.  Protein lysine acetylation by p300/CBP.

Authors:  Beverley M Dancy; Philip A Cole
Journal:  Chem Rev       Date:  2015-01-16       Impact factor: 60.622

Review 6.  Epigenetics of the failing heart.

Authors:  José Marín-García; Alexander T Akhmedov
Journal:  Heart Fail Rev       Date:  2015-07       Impact factor: 4.214

7.  Effective Quenchers Are Required to Eliminate the Interference of Substrate: Cofactor Binding in the HAT Scintillation Proximity Assay.

Authors:  Liza Ngo; Jiang Wu; Chao Yang; Yujun George Zheng
Journal:  Assay Drug Dev Technol       Date:  2015-05-28       Impact factor: 1.738

Review 8.  Readers, writers, and erasers: chromatin as the whiteboard of heart disease.

Authors:  Thomas G Gillette; Joseph A Hill
Journal:  Circ Res       Date:  2015-03-27       Impact factor: 17.367

9.  The CRM1 nuclear export receptor controls pathological cardiac gene expression.

Authors:  Brooke C Harrison; Charles R Roberts; David B Hood; Meghan Sweeney; Jody M Gould; Erik W Bush; Timothy A McKinsey
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

Review 10.  Matrix revisited: mechanisms linking energy substrate metabolism to the function of the heart.

Authors:  Andrew N Carley; Heinrich Taegtmeyer; E Douglas Lewandowski
Journal:  Circ Res       Date:  2014-02-14       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.